The Article related to p27kip1 degradation inhibitor heterocyclic carbamate preparation, heterocyclic carboxylic acid hydrazide preparation, cyclin dependent kinase inhibitor protein p27kip1 degradation inhibitor, cell proliferative disease prevention treatment, cancer rheumatism diabetes obesity endometriosis prevention treatment and other aspects.SDS of cas: 19989-66-3
On January 5, 2012, Uchida, Hiroshi; Asagarasu, Akira; Matsui, Teruaki published a patent.SDS of cas: 19989-66-3 The title of the patent was Preparation of heterocyclic carbamate and carboxylic acid hydrazide compounds as p27Kip1 degradation inhibitors. And the patent contained the following:
There are provided novel heterocyclic compounds and salts thereof applicable in the selective inhibition of the degradation of cyclin-dependent kinase inhibitor protein (p27Kip1) for the prevention and/or treatment of cell proliferative diseases such as cancer, rheumatism, diabetes, obesity, endometriosis, prostatic hypertrophy (prostatic hyperplasia), and inflammation. The title compounds and salts thereof represented in formula [I; A represents an alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group, and group A can have a substituent group; ring B represents a 5- to 8- membered monocyclic heterocyclic ring or a condensed ring containing this monocyclic heterocyclic ring, and ring B can have a substituent group; ring C represents an aromatic ring, and ring C can have a substituent group; L represents a linker having 3-5 atoms in the main chain selected from carbon atoms, nitrogen atoms, oxygen atoms, and sulfur atoms, and having at least one heteroatom selected from nitrogen atoms, oxygen atoms, and sulfur atoms, and linker L can have a substituent group; and n represents 0 or 1.] are prepared Thus, 1.11 g 2-(4-chloro-2-methoxyphenyl)-4-methylthiazole-5-carboxylic acid and 870 mg (1,2,3,4-Tetrahydrobenzo[d]pyrido[2,1-b]imidazol-7-yl)methanol were suspended in 50 mL toluene, successively treated with 475 mg Et3N and 1.18 g diphenylphosphoryl azide, and refluxed for 2 h to give, after workup and silica gel chromatog., 71% [2-(4-chloro-2-methoxyphenyl)-4-methylthiazol-5-yl]carbamic acid 1,2,3,4-tetrahydrobenzo[d]pyrido[2,1-b]imidazol-7-ylmethyl ester (II). II and 3-pyrazolylmethyl 5-benzimidazolylcarbamate derivative (III) in vitro induced apoptosis of human prostatic cancer cells (PC-3 cells) at 0.025 and 0.00625 μM, resp., and in vitro showed IC50 of 6.70 and 0.43 nM, resp., against PC-3 cells. The experimental process involved the reaction of Benzo[d]thiazol-6-ylmethanol(cas: 19989-66-3).SDS of cas: 19989-66-3
The Article related to p27kip1 degradation inhibitor heterocyclic carbamate preparation, heterocyclic carboxylic acid hydrazide preparation, cyclin dependent kinase inhibitor protein p27kip1 degradation inhibitor, cell proliferative disease prevention treatment, cancer rheumatism diabetes obesity endometriosis prevention treatment and other aspects.SDS of cas: 19989-66-3
Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica